Veru Inc

Veru's enobosarm combined with Wegovy demonstrated reduced gastrointestinal side effects compared to Wegovy alone in a 168-person Phase 2 trial.

Phase IIb QUALITY trial demonstrates significant improvements in lean mass retention and fat loss when combining enobosarm with semaglutide, compared to placebo.

Veru's enobosarm significantly reduced lean mass loss in older, overweight or obese patients taking Wegovy, a GLP-1 receptor agonist, in a Phase 2b trial.

Veru Inc. announced positive topline results from its Phase 2b QUALITY study, where enobosarm significantly reduced lean mass loss in patients on WEGOVY.

Veru Inc. has commenced its Phase 2b QUALITY trial, evaluating enobosarm combined with semaglutide for sarcopenic obesity, with 168 patients enrolled.

• Veru Inc. has commenced a Phase 2 clinical trial evaluating the combination of enobosarm and abemaciclib for AR+ ER+ HER2- metastatic breast cancer. • The trial aims to assess the efficacy and safety of the combination therapy in patients who have progressed on prior endocrine therapy and CDK4/6 inhibitors. • Enobosarm, a selective androgen receptor modulator (SARM), is being investigated for its potential to enhance the effectiveness of abemaciclib in this specific breast cancer subtype. • The study targets a patient population with androgen receptor-positive, estrogen receptor-positive, and HER2-negative metastatic breast cancer, addressing a significant unmet need.

Eli Lilly's Zepbound demonstrated superior weight loss compared to Novo Nordisk's Wegovy in a head-to-head trial, with Zepbound users losing over 20% of body weight versus Wegovy's under 14%.

A meta-analysis of four randomized clinical trials suggests that enobosarm may optimize weight loss by preserving muscle mass.